GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers.

Original title: “GSK, Hansoh ADC extends survival in lung cancer study”

paraneoplastic neurologic syndrome in advanced lung cancer with mixed adenocarcinoma and squamous features a diagnostic challenge a case report

Original title: “Paraneoplastic neurologic syndrome in advanced lung cancer with mixed adenocarcinoma and squamous features: a diagnostic challenge-a case report.”

Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.

Original title: “Merck, Gilead report mixed outcomes in key lung cancer, HIV studies”

While Merck and Gilead Sciences reported back-to-back late-stage victories for their weekly HIV pill, the partners also discontinued a Phase 3 program for their cancer combo after disappointing lung cancer survival data.

Original title: “Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble”

While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.

Original title: “Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?”

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data are expected later this year.

Original title: “ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come”

Practice-changing data in lung cancer, prostate cancer and more were on display over the weekend at the American Society of Clinical Oncology annual meeting in Chicago. Plus, early readouts on assets that could reshape the cancer landscape.

Original title: “ASCO: A battle of bispecifics, Eli Lilly’s big win and more”

“King Keytruda's reign continues,” analysts at BMO Capital Markets declared after Chinese data for Summit Therapeutics’ ivonescimab were revealed at the American Society for Clinical Oncology in Chicago.

Original title: “ASCO: Summit reached with China lung data but new climb begins to prove global benefit”

Interim overall survival data on a TROP2 ADC from Merck and Chinese partner Kelun-Biotech provide support for the pharma’s big bet on its potential to help navigate Keytruda’s impending loss of exclusivity.

Original title: “ASCO: Kelun-Merck ADC shines with differentiated overall survival in first-line lung cancer”

Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous data from Akeso’s HARMONi-6 trial left them wanting.

Original title: “ASCO: Akeso’s VEGF/PD-1 boosts lung cancer survival, relieving pressure on US partner Summit”

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies known as "PD-1/VEGF inhibitors."

Original title: “Akeso, Summit drug extends survival in closely watched lung cancer trial”

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.

Original title: “Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival”

hepatoid adenocarcinoma of the lung clinicopathologic and molecular analysis of 17 cases

Original title: “Hepatoid adenocarcinoma of the lung: clinicopathologic and molecular analysis of 17 cases.”

David Ross: Continuing Advocacy for Rare Diseases Two Decades After Losing a Loved One / cancer, David Ross, IPF, Karen Yada Ross, Lung cancer, Natera, Karen continues to advocate for rare diseases such as PH-ILD with a sense of dedication, humility, and compassion. As part of the Pulmovant team, she aspires to make a meaningful difference for these courageous patients.”

Original title: “David Ross: Continuing Advocacy for Rare Diseases Two Decades After Losing a Loved One - OncoDaily”

primary hepatoid adenocarcinoma of the lung with signet ring cell differentiation and widespread osseous metastases a case report

Original title: “Primary Hepatoid Adenocarcinoma of the Lung With Signet Ring Cell Differentiation and Widespread Osseous Metastases: A Case Report.”

declining incidence of large cell lung carcinoma in the united states effects of who reclassification in a seer analysis

Original title: “Declining Incidence of Large Cell Lung Carcinoma in the United States: Effects of WHO Reclassification in a SEER Analysis.”

gastroparesis following anatomical resection for lung cancer clinical characteristics and implications

Original title: “Gastroparesis following anatomical resection for lung cancer: clinical characteristics and implications.”

As a result, targeted radionuclide ... of new treatment approaches, tailored to the nature and biology of different tumors. Later this year, a UK-based biotech company called Nuclide Therapeutics, is planning a clinical trial in lung cancer patients, a population with notoriously low overall survival rates. “The symptoms don’t often show until the disease has spread, ... As a result, targeted radionuclide therapy is set to become ever more varied and sophisticated in the coming years and could ultimately lead to a broad array of new treatment approaches, tailored to the nature and biology of different tumors. Later this year, a UK-based biotech company called Nuclide Therapeutics, is planning a clinical trial in lung cancer patients, a population with notoriously low overall survival rates. “The symptoms don’t often show until the disease has spread, making surgery difficult, and the cancer develops therapy resistance at a rapid rate,” says Tim Witney, professor of molecular imaging at King’s College London, and the company’s co-founder & CSO. Breakthroughs in identifying tumor biomarkers in liver, gastric, prostate, lung and other cancers and are accelerating radionuclide therapies. After being approved by the FDA in early 2022, it has emerged as a novel life-extending option for patients with advanced disease. ... The success of this drug has resulted in PSMA becoming a focal point for other radionuclide therapies aimed at advanced prostate cancer. Bayer has two early-stage clinical trials in progress using PSMA to deliver higher energy radionuclides to patients with metastatic disease. But once there’s data that shows, ‘Ok, this is safe and also as effective as standard treatments,’ then radiopharmaceuticals could be moved up as a first-line option where it’s the patient’s and physician’s choice about which treatment they want to receive.” · I look forward to watching these clinical trials carefully over the coming years—and one day, hopefully, welcoming a new standard tool into our toolbox for treating cancer.

Original title: “Precision Radiation Therapy Could Offer New Hope For Hard-To-Treat Cancers”

carcinomas and carcinoid tumors of the lungs and bronchi in children and adolescents the expert recommendations

Original title: “Carcinomas and Carcinoid Tumors of the Lungs and Bronchi in Children and Adolescents: The EXPeRT Recommendations.”

placental transmogrification of the lung misdiagnosed as cavitary lung cancer a case report

Original title: “[Placental transmogrification of the lung misdiagnosed as cavitary lung cancer: a case report].”